Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Feb 28, 2014; 20(8): 1972-1985
Published online Feb 28, 2014. doi: 10.3748/wjg.v20.i8.1972
Perioperative anemia management in colorectal cancer patients: A pragmatic approach
Manuel Muñoz, Susana Gómez-Ramírez, Elisa Martín-Montañez, Michael Auerbach
Manuel Muñoz, Transfusion Medicine, School of Medicine, University of Málaga, 29071-Málaga, Spain
Susana Gómez-Ramírez, Internal Medicine, University Hospital Virgen de la Victoria, 29071-Málaga, Spain
Elisa Martín-Montañez, Department of Pharmacology, School of Medicine, University of Málaga, 29071-Málaga, Spain
Michael Auerbach, Georgetown University School of Medicine, Washington, DC 20057, United States
Author contributions: All the authors contributed equally on conception and design, acquisition of data, or analysis and interpretation of data; drafting the article or revising it critically for important intellectual content; and final approval of the version to be published.
Correspondence to: Manuel Muñoz, Professor, Transfusion Medicine, School of Medicine, University of Málaga, Campus de Teatinos, s/n. 29071-Málaga, Spain. mmunoz@uma.es
Telephone: +34-952-131540 Fax: +34-952-1315340
Received: September 17, 2013
Revised: December 21, 2013
Accepted: January 19, 2014
Published online: February 28, 2014
Processing time: 162 Days and 9.9 Hours
Abstract

Anemia, usually due to iron deficiency, is highly prevalent among patients with colorectal cancer. Inflammatory cytokines lead to iron restricted erythropoiesis further decreasing iron availability and impairing iron utilization. Preoperative anemia predicts for decreased survival. Allogeneic blood transfusion is widely used to correct anemia and is associated with poorer surgical outcomes, increased post-operative nosocomial infections, longer hospital stays, increased rates of cancer recurrence and perioperative venous thromboembolism. Infections are more likely to occur in those with low preoperative serum ferritin level compared to those with normal levels. A multidisciplinary, multimodal, individualized strategy, collectively termed Patient Blood Management, minimizes or eliminates allogeneic blood transfusion. This includes restrictive transfusion policy, thromboprophylaxis and anemia management to improve outcomes. Normalization of preoperative hemoglobin levels is a World Health Organization recommendation. Iron repletion should be routinely ordered when indicated. Oral iron is poorly tolerated with low adherence based on published evidence. Intravenous iron is safe and effective but is frequently avoided due to misinformation and misinterpretation concerning the incidence and clinical nature of minor infusion reactions. Serious adverse events with intravenous iron are extremely rare. Newer formulations allow complete replacement dosing in 15-60 min markedly facilitating care. Erythropoiesis stimulating agents may improve response rates. A multidisciplinary, multimodal, individualized strategy, collectively termed Patient Blood Management used to minimize or eliminate allogeneic blood transfusion is indicated to improve outcomes.

Keywords: Colorectal cancer; Anemia; Allogeneic blood transfusion; Intravenous iron; Erythropoiesis stimulating agents; Patient Blood Management

Core tip: Anemia, usually due to iron deficiency, is highly prevalent among patients with colorectal cancer. Both anemia and allogeneic blood transfusion are associated with poorer outcomes. Anemia management, within a multidisciplinary, multimodal, individualized strategy to minimize or eliminate allogeneic blood transfusion, is indicated to improve outcomes. Intravenous iron is safe and effective but underused, despite the extremely low risk of causing serious adverse events. Newer intravenous iron formulations allow complete replacement dosing in 15-60 min markedly facilitating care. Erythropoiesis stimulating agents may improve response rates.